| NovaBiotics Ltd | NP339 | | Protein/Peptide | Aspergillus spp, Candida spp, Mucorales, Candida auris/Prophylaxis and treatment of fungal disease | Pre-clinical |
| NovaBiotics Ltd | NM002-IV | | Other | Broad-spectrum G+/G-/Community acquired pneumonia (CAP) | Phase III |
| VibioSphen | Therapeptics | 3a | Protein/Peptide | A. baumannii; P. aeruginosa; Klebsiella pneumoniae; Staphylococcus aureus; Clostridioides difficile/Intra-abdominal infections (cIAI) | Lead opt |
| Summit Therapeutics plc | DDS-01 Series | 3a | NME | Neisseria gonorrhoeae/Gonorrhoea | Lead opt |
| Mileutis Ltd. | Peptide(s) hydrolyzed from casein | | Protein/Peptide | P. aeruginosa; Enterobacter spp.; Salmonella spp | Pre-clinical |
| Helperby Therapeutics Ltd | HY-007 Infusion | 3d/5a | Other | Acinetobacter baumannii/Lung, blood. CNS and skin/soft tissue structure infections | Lead opt |
| Helperby Therapeutics Ltd | HY-001 Infusion | 3d/5a | Other | Escherichia coli, Klebsiella spp/Intra-abdominal infections | Phase I |
| NovaBiotics Ltd | NP432 | 3a | Protein/Peptide | A. baumannii; P. aeruginosa; Enterobacter spp.; Clostridioides difficile | Pre-clinical |
| NovaBiotics Ltd | NP108 | 1b | Protein/Peptide | Staphylococcus aureus; Enterococcus faecium; Streptococcus pneumoniae | Pre-clinical |
| Phico Therapeutics Ltd | SASPject™ PT9 | 3a | Phage | S. aureus/Animal Health | Lead opt |
| Phico Therapeutics Ltd | SASPject™ PT8 | 3a | Phage | S. aureus/Bacteraemia | Lead opt |
| Phico Therapeutics Ltd | SASPject™ PT3.9 | 3a | Phage | P. aeruginosa/Hospital-acquired or Ventilator-acquired bacterial pneumoniae (HABP/VABP) | Pre-clinical |
| Nabriva Therapeutics GmbH | Next Generation Pleuromutilins | 3d | NME | Resistant Gram-positive and Gram-negative bacterial organisms/Community acquired pneumonia (CAP) and ABSSSI | Lead opt |
| Nabriva Therapeutics GmbH | Lefamulin | 3a | NME | Staphylococcus aureus; Haemophilus influenzae/Bacterial exacerbations in patients with cystic fibrosis | Phase I |
| Nabriva Therapeutics GmbH | Lefamulin | 3a | NME | Neisseria gonorrhoea; Mycoplasma genitalium; Chlamydia trachomatis/Sexually transmitted infections (STI) | Phase I |
| Da Volterra | DAV361 | 4b | Other | A. baumannii; P. aeruginosa; Enterobacter spp.; Enterococcus faecium; Clostridioides difficile / Prevention of colonization by resistant bacteria and subsequent infections in patients hospitalized in ICUs | Lead opt |
| Basilea | Novel target (IspF inhibitor) | 3a | NME | A. baumannii; P. aeruginosa; Escherichia coli; Klebsiella pneumoniae; Enterobacter spp.; Citrobacter spp.; Proteus spp.; Salmonella spp; Shigella spp.; Other Enterobacterales / Hospital-acquired or Ventilator-acquired bacterial pneumoniae (HABP/VABP) | Discovery |
| Basilea | Novel target (DXR inhibitor) | 3a | NME | A. baumannii; P. aeruginosa; Escherichia coli; Klebsiella pneumoniae; Enterobacter spp.; Citrobacter spp.; Proteus spp.; Salmonella spp; Shigella spp.; Other Enterobacterales / Hospital-acquired or Ventilator-acquired bacterial pneumoniae (HABP/VABP) | Lead opt |
| Basilea | Novel class | 3a | NME | A. baumannii; P. aeruginosa; Escherichia coli; Klebsiella pneumoniae; Enterobacter spp.; Citrobacter spp.; Proteus spp.; Salmonella spp; Shigella spp.; Other Enterobacterales / Hospital-acquired or Ventilator-acquired bacterial pneumoniae (HABP/VABP) | Lead opt |
| Basilea | Novel class | 3a | NME | Aspergillus spp; Mucorales; Fusarium spp; Scedosporium spp; Cryptococcus spp; Candida spp / Invasive fungal disease | Lead opt |
| Destiny Pharma plc | XF-73 | 1b | NME | Staphylococcus aureus; Enterococcus faecium; Streptococcus pneumoniae / Prevention of oral mucositis | Pre-clinical |
| Destiny Pharma plc | XF-73 | 3a | NME | Staphylococcus aureus; Enterococcus faecium; Streptococcus pneumoniae / Burns | Pre-clinical |
| Destiny Pharma plc | XF-73 | 3a | NME | Staphylococcus aureus; Enterococcus faecium; Streptococcus pneumoniae / Treatment of chronic rhinosinusitis | Pre-clinical |
| Destiny Pharma plc | XF-73 | 3a | NME | Staphylococcus aureus; Enterococcus faecium; Streptococcus pneumoniae / Cystic fibrosis associated infections | Pre-clinical |
| Destiny Pharma plc | XF-73 | 3a | NME | Staphylococcus aureus; Enterococcus faecium; Streptococcus pneumoniae / Prevention of post-surgical infection | Phase II |
| Destiny Pharma plc | NTCD-M3 | 1b | NME | Toxigenic strains of C. difficile / Prevention of recurrence of C diff infection | Phase II |
| Destiny Pharma plc | SPOR-COV | 1a | NME | Respiratory viruses, SARS-COV-2 & Influenza / Prevention of viral respiratory infections | Pre-clinical |
| Infex Therapeutics Ltd | RESP-X | 3c | Antibody | P. aeruginosa / Non-cystic-fibrosis bronchiectasis | Phase I |
| Infex Therapeutics Ltd | MET-X | 3d | NME | A. baumannii; P. aeruginosa; Escherichia coli; Klebsiella pneumoniae; Enterobacter spp. / Complicated urinary tract infections (cUTI), HAP, VAP, bloodstream infections, intra-abdominal infections | Pre-clinical |
| Infex Therapeutics Ltd | COV-X | - | Other | Pan-coronavirus / Coronavirus infections | Lead opt |
| Infex Therapeutics Ltd | RDX-02 | 3a | NME | A. baumannii; P. aeruginosa; Escherichia coli; Klebsiella pneumoniae; Enterobacter spp. / Gram-negative AMR infections | Discovery |
| Infex Therapeutics Ltd | PAN-X | - | Other | Pan-coronavirus / Coronavirus infections | Discovery |
| AdjuTec Pharma AS | APC247 | 3d | NME | Escherichia coli; Klebsiella pneumoniae / complicated urinary tract infections (cUTI) | Pre-clinical |
| Ultupharma AB | ULT2 | 3a | NME | A. baumannii; P. aeruginosa; Escherichia coli; Klebsiella pneumoniae; Enterobacter spp.; Salmonella spp; Shigella spp.; Helicobacter pylori; Haemophilus influenzae; Staphylococcus aureus; Streptococcus pneumoniae / Bloodstream infections | Pre-clinical |
| Ultupharma AB | ULT3 | 3a | Protein/Peptide | A. baumannii; P. aeruginosa; Escherichia coli; Klebsiella pneumoniae; Enterobacter spp.; Staphylococcus aureus / Bloodstream infections | Lead opt |
| VAXDYN | KapaVax | 1a | Vaccine | Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter baumannii/Community acquired pneumonia (CAP) and other upper respiratory infections (URTI) (sinusitis/otitis media etc) | Pre-clinical |
| Spexis AG | LptA-OMPTA | 3a | Protein/Peptide | Escherichia coli; Klebsiella pneumoniae; Enterobacter spp.; Citrobacter spp. / HABP/VABP, cUTI, cIAI | Lead opt |
| F2G Ltd | Olorofim | 3a | NME | DHODH inhibitor/Aspergillosis refractory, resistant or intolerant; Lomentospora prolificans, Scedosporium, Fusarium and Scopulariopsis species; Coccidioidomycosis refractory | Phase III |
| AdjuTec Pharma AS | APC148 | 3d | NME | Klebsiella pneumoniae; Enterobacter spp / complicated urinary tract infections (cUTI) | IND/CTA ready |
| Diotheris SAS | DECOLONIZE | 1b | Other | S. aureus/Decolonization of multi-resistant S. aureus | Discovery |
| Diotheris SAS | PREVENT | 1b | Other | S. aureus/Prevent infection by multi-resistant S. aureus | Pre-clinical |
| Aptorum Group Ltd | ALS-3 | 3d | Other | Staphylococcus aureus; Enterococcus faecium; Streptococcus pneumoniae//Treatment of gram+ve bacterial infections | Lead opt |
| Aptorum Group Ltd | ALS-2 | 4a | Other | Staphylococcus aureus; Enterococcus faecium; Streptococcus pneumoniae/Treatment of gram+ve bacterial infections | Lead opt |
| Aptorum Group Ltd | ALS-1 | 3a | Other | Influenza virus A//Treatment of viral infections | Lead opt |
| Aptorum Group Ltd | ALS-4 | 3c | Other | S. aureus//Treatment of bacterial infections | Phase I |
| Debiopharm International | Debio 1454/S | 3a | NME | A. baumannii/Hospital-acquired or Ventilator-acquired bacterial pneumoniae (HABP/VABP) | Lead opt |
| OLGRAM | Ol20-01 | 5a | Protein/Peptide | P. aeruginosa; Broad-spectrum G+/G-/Cystic fibrosis associated infections | Pre-clinical |
| Selmod GmbH | slm 500 | 3a | NME | Escherichia coli; Broad-spectrum G+/G-/Complicated urinary tract infections (cUTI) | Pre-clinical |
| Selmod GmbH | slm 400 | 3a | NME | A. baumannii; Broad-spectrum G+/G-/Hospital-acquired or Ventilator-acquired bacterial pneumoniae (HABP/VABP) | Pre-clinical |
| Selmod GmbH | slm 300 | 3a | NME | Klebsiella pneumoniae; Broad-spectrum G+/G-/Hospital-acquired or Ventilator-acquired bacterial pneumoniae (HABP/VABP) | Pre-clinical |
| Selmod GmbH | slm 200 | 3a | Protein/Peptide | Candida albicans, Aspergillus fumigatus, Candida auris/Invasive aspergillosis, Oral Candidiasis, Bronchopulmonary aspergillosis | Lead opt |
| Selmod GmbH | slm 100 | 3a | NME | Candida albicans, Aspergillus fumigatus, Candida auris/Invasive aspergillosis, Oral Candidiasis, Bronchopulmonary aspergillosis | Lead opt |
| BioNTech R&D | PM-477 | 3a | Protein/Peptide | Gardnerella/Bacterial vaginosis | Pre-clinical |
| Nabriva Therapeutics GmbH | BC-2126 | 3a | NME | A. baumannii; P. aeruginosa; Enterobacterales/Hospital-acquired or Ventilator-acquired bacterial pneumonia (HABP/VABP) | Pre-clinical |
| Nabriva Therapeutics GmbH | BC-7013 | 3a | NME | Staphylococcus aureus; ß-hemolytic Streptococcus spp.; coagulase-negative Staphylococcus spp./Topical treatment of skin and skin structure infections | Phase I |
| AiCuris Anti-infective Cures AG | NPI Scaffolds | 3a | NME | Undisclosed/Healthcare-asscoiated infections | Lead opt |
| AiCuris Anti-infective Cures AG | Macrocyles | 3a | NME | Undisclosed | Lead opt |
| Pherecydes Pharma | PP970 | 3a | Phage | Escherichia coli/Complicated urinary tract infections (cUTI) | Pre-clinical |
| Pherecydes Pharma | PP954 | 3a | Phage | Escherichia coli/Complicated urinary tract infections (cUTI) | Pre-clinical |
| Pherecydes Pharma | PP814 | 3a | Phage | Escherichia coli/Complicated urinary tract infections (cUTI) | Pre-clinical |
| Pherecydes Pharma | PP700 | 3a | Phage | Escherichia coli/Complicated urinary tract infections (cUTI) | Pre-clinical |
| Assuré Medical Limited | Sol-UTI | 1b | Other | P. aeruginosa; Escherichia coli; Klebsiella pneumoniae; Enterobacter spp.; Proteus spp.; Staphylococcus aureus / Uncomplicated urinary tract infections (uUTI) | Pre-clinical |
| BioVersys AG | BV100 | 3a | NME | A. baumannii/HAP, VAP, BSI | Phase I |
| Madam Therapeutics BV | P10 | 3a | Protein/Peptide | A. baumannii/Hospital-acquired or Ventilator-acquired bacterial pneumoniae (HABP/VABP) | Lead opt |
| Alphanosos | W5P1 + WXPYY (more potent lead) | | Other | N. gonorrhoeae; S. aureus/Gonorrhoea | IND/CTA ready |
| ABAC therapeutics | ABAC-40244 | 3a | NME | Staphylococcus aureus/Hospital infections | Lead opt |
| ABAC therapeutics | ABAC-40411 | 3a | NME | Streptococcus pneumoniae/Community acquired pneumonia (CAP) and other upper respiratory infections (URTI) (sinusitis/otitis media etc) | Lead opt |
| ANTABIO S.A.S | SBLi (ANT3310) | 3d | NME | A. baumannii; P. aeruginosa; Escherichia coli; Klebsiella pneumoniae; Enterobacter spp.; Citrobacter spp.; Proteus spp.; Salmonella spp; Shigella spp.; Other Enterobacterales; Haemophilus influenzae / Hospital-acquired or Ventilator-acquired bacterial pneumoniae (HABP/VABP) | IND/CTA ready |
| VibioSphen | Sativa | 3b | NME | P. aeruginosa | Pre-clinical |
| VAXDYN | AcinetoVax | 1a | Vaccine | Acinetobacter baumannii/Hospital-acquired or Ventilator-acquired bacterial pneumoniae (HABP/VABP) | Pre-clinical |
| Summit Therapeutics plc | SMT026738 | 3a | NME | Escherichia coli; Klebsiella pneumoniae; Enterobacter spp.; Citrobacter spp./Complicated urinary tract infections (cUTI) | Pre-clinical |
| Summit Therapeutics plc | Ridinilazole | 3a | NME | C. difficile infections | Phase III |
| QureTech Bio AB | TIB | 3a | NME | C. trachomatis / Ocular Chlamydia infection | Lead opt |
| QureTech Bio AB | GmP | 3d | NME | Staphylococcus aureus; Enterococcus faecium; Clostridioides difficile; E. faecalis; S. epidermidis / Complicated urinary tract infections (cUTI) | Lead opt |
| QureTech Bio AB | CIB | 3a | NME | C. trachomatis / Genital Chlamydia infection | Lead opt |
| QureTech Bio AB | MTI | 3d | NME | Mycobacterium tuberculosis / Tuberculosis | Lead opt |
| Spexis AG | Murepavadin (inhaled) | 3a | Protein/Peptide | P. aeruginosa / Cystic fibrosis associated infections | Phase I |
| Spexis AG | ColiFin® | 3a | Protein/Peptide | A. baumannii; P. aeruginosa; Escherichia coli; Klebsiella pneumoniae / Cystic fibrosis associated infections | Phase III |
| Pherecydes Pharma | PN1777 | 3a | Phage | P. aeruginosa/Hospital-acquired or Ventilator-acquired bacterial pneumoniae (HABP/VABP) | IND/CTA ready |
| Pherecydes Pharma | PN1792 | 3a | Phage | P. aeruginosa/Hospital-acquired or Ventilator-acquired bacterial pneumoniae (HABP/VABP) | IND/CTA ready |
| Pherecydes Pharma | PN1797 | 3a | Phage | P. aeruginosa/Hospital-acquired or Ventilator-acquired bacterial pneumoniae (HABP/VABP) | IND/CTA ready |
| Pherecydes Pharma | PN1493 | 3a | Phage | Staphylococcus aureus/Prosthetic Joint infections (PJI) | IND/CTA ready |
| Pherecydes Pharma | PN1815 | 3a | Phage | Staphylococcus aureus/Prosthetic Joint infections (PJI) | IND/CTA ready |
| Pherecydes Pharma | PN1450 | 3a | Phage | P. aeruginosa/Hospital-acquired or Ventilator-acquired bacterial pneumoniae (HABP/VABP) | IND/CTA ready |
| Omnix Medical | OMN6 | 3a/5a | Protein/Peptide | A. baumannii; P. aeruginosa; Escherichia coli; Klebsiella pneumoniae; Enterobacter spp/Hospital-acquired or Ventilator-acquired bacterial pneumoniae (HABP/VABP) | Phase I |
| NovaBiotics Ltd | NM001 inhaled Lynovex® | 1b | Other | Broad-spectrum G+/G-/Cystic fibrosis associated infections | IND/CTA ready |
| NovaBiotics Ltd | NM001 oral Lynovex® | 3d | Other | Broad-spectrum G+/G-/Cystic fibrosis associated infections | Phase II |
| Nosopharm | NOSO-2G | 3a | NME | A. baumannii; P. aeruginosa; Escherichia coli; Klebsiella pneumoniae; Enterobacter spp.; Citrobacter spp.; Proteus spp.; Salmonella spp; Shigella spp.; Other Enterobacterales/Hospital-acquired or Ventilator-acquired bacterial pneumoniae (HABP/VABP) | Lead opt |
| Nosopharm | NOSO-502 | 3a | NME | Escherichia coli; Klebsiella pneumoniae; Enterobacter spp.; Citrobacter spp.; Proteus spp.; Salmonella spp; Shigella spp.; Other Enterobacterales; Staphylococcus aureus/Complicated urinary tract infections (cUTI) | IND/CTA ready |
| Northern Antibiotics Oy (Ltd) | NAB815 | 3a | Protein/Peptide | A. baumannii; Enterobacter spp./Complicated urinary tract infections (cUTI) | Lead opt |
| Northern Antibiotics Oy (Ltd) | NAB739 | 3a | Protein/Peptide | A. baumannii; Enterobacter spp./Complicated urinary tract infections (cUTI) | Lead opt |
| Nabriva Therapeutics GmbH | Lefamulin | 3a | NME | Haemophilus influenzae; Staphylococcus aureus; Streptococcus pneumoniae; Legionella pneumophila; Mycoplasma pneumoniae; Chlamydophila pneumoniae; beta-hemolytic Streptococcus spp.; Viridans group Streptococcus spp.; Staphylococcus spp./CAP and URTI in pediatric patients | Phase I |
| Nabriva Therapeutics GmbH | Lefamulin | 3a | NME | Staphylococcus aureus; beta-hemolytic Streptococcus spp.; Viridans group Streptococcus spp.; Staphylococcus spp./Acute bacterial skin and skin structure infections (ABSSSI) | Phase II |
| Nabriva Therapeutics GmbH | Lefamulin | 3a | NME | Haemophilus influenzae; Staphylococcus aureus; Streptococcus pneumoniae; Legionella pneumophila; Mycoplasma pneumoniae; Chlamydophila pneumoniae; beta-hemolytic Streptococcus spp.; Viridans group Streptococcus spp.; Staphylococcus spp./Community acquired pneumonia (CAP) | Marketed |
| Mutabilis SAS | 2G-Dabocin | 3a | NME | Enterobacterales, P. aeruginosa, A. baumannii/Complicated urinary tract infections (cUTI) | Lead opt |
| Mutabilis SAS | EBL-1463 | 3a | NME | Enterobacterales/Complicated urinary tract infections (cUTI) | Pre-clinical |
| Madam Therapeutics BV | SAAP-148 | 3a | Protein/Peptide | Broad-spectrum G+/G-/Complicated urinary tract infections (cUTI) | Lead opt |
| IMMUNETHEP, SA | Unimab | 3c | Antibody | Escherichia coli; Klebsiella pneumoniae; Staphylococcus aureus; Streptococcus pneumoniae; S. agalactiae/Bloodstream infections | Pre-clinical |
| IMMUNETHEP, SA | PNV | 1a | Vaccine | S. aureus, E. Coli, ETEC/Bloodstream infections, Community acquired pneumonia (CAP) and other upper respiratory infections (URTI) (sinusitis/otitis media etc) | Pre-clinical |
| Hypharm GmbH | HY-133 | 1b | Phage | Staphylococcus aureus/Nasal colonization with MRSA | IND/CTA ready |
| Helperby Therapeutics Ltd | HY-001 Infusion | 3d/5a | Other | Escherichia coli, Klebsiella spp/Complicated urinary tract infections (cUTI) | Phase II |
| Helperby Therapeutics Ltd | HY-003 Infusion | 3d/5a | Other | Escherichia coli, Klebsiella spp/Skin/soft tissue structure, lung, blood and CNS infections | Pre-clinical |
| Helperby Therapeutics Ltd | HY-004 Inhalation | 3d/5a/1d | Other | P. aeruginosa; Staphylococcus aureus including MRSA/Cystic fibrosis associated infections | Pre-clinical |
| Helperby Therapeutics Ltd | HY-005 Infusion | 3d/5a | Other | P. aeruginosa; Staphylococcus aureus including MRSA/Lung, blood. CNS and skin/soft tissue structure infections | Lead opt |
| Eligo Bioscience | EB004 | 1b | Phage | Escherichia coli; Klebsiella pneumoniae/Bloodstream infections | Pre-clinical |
| DEINOVE | DNV3837 | 3a | NME | C. difficile infections | Phase II |
| Debiopharm International | Debio 1453 | 3a | NME | Neisseria gonorrhoeae; C. trachomatis/Gonorrhoea | Pre-clinical |
| Debiopharm International | Afabicin (Debio 1450) | 3a | NME | ABSSI (caused by S. aureus), osteomyelitis | Phase II |
| Combioxin SA | CAL02 | 4a | Other | Virulence factors, broad spectrum Gram+ and Gram-, resistance agnostic/Severe community-acquired bacterial pneumonia | Phase II |
| Centauri Therapeutics Ltd | ABX01 | 3c | Other | A. baumannii; P. aeruginosa; Escherichia coli; Klebsiella pneumoniae; Enterobacter spp./Healthcare-asscoiated infections | Pre-clinical |
| Centauri Therapeutics Ltd | ABX02 | 3c | Other | P. aeruginosa/Healthcare-asscoiated infections | Pre-clinical |
| BioVersys AG | BV200 | 4a | NME | Staphylococcus aureus/Hospital-acquired or Ventilator-acquired bacterial pneumoniae (HABP/VABP) | Lead opt |
| BioVersys AG | BV300 | 3a | NME | A. baumannii; P. aeruginosa; Enterobacter spp.; Staphylococcus aureus; Enterococcus faecium/Hospital-acquired or Ventilator-acquired bacterial pneumoniae (HABP/VABP) | Lead opt |
| BioVersys AG | BVL-GSK098 | 3d | NME | M. tuberculosis/Tuberculosis | Phase I |
| BioFilm Pharma | BFP002 | 3e | NME | A. baumannii; P. aeruginosa; Escherichia coli; Klebsiella pneumoniae; Staphylococcus aureus; Enterococcus faecium/Cystic fibrosis associated infections | Lead opt |
| BioFilm Pharma | BFP101 | 3e | NME | Staphylococcus aureus/Local-Diabetic Foot Ulcer | Lead opt |
| BioFilm Pharma | BFP102 | 3e | NME | A. baumannii; P. aeruginosa; Escherichia coli; Klebsiella pneumoniae; Staphylococcus aureus; Enterococcus faecium/Cystic fibrosis associated infections | Lead opt |
| BioFilm Pharma | BFP001 | 3e | NME | Staphylococcus aureus/Local - Diabetic Foot Ulcer | Lead opt |
| Basilea | Ceftobiprole | 3a | NME | S. aureus (including MRSA); Streptococcus spp; Enterococcus faecalis; Enterobacterales; P. aeruginosa / Staphylococcus aureus bacteremia; Acute bacterial skin and skin structure infections | Phase III |
| Basilea | Ceftobiprole | 3a | NME | S. aureus (including MRSA); Streptococcus spp; Enterococcus faecalis; Enterobacterales; P. aeruginosa; Haemophilus influenzae / CAP, HAP | Marketed |
| ANTABIO S.A.S | PEi (ANT3273) | 3c/1b/4a/4b | NME | P. aeruginosa / Non-CF bronchiectasis associated infections | Pre-clinical |
| ANTABIO S.A.S | MBLi (ANT2681) | 3d | NME | Escherichia coli; Klebsiella pneumoniae; Enterobacter spp.; Citrobacter spp.; Proteus spp.; Salmonella spp; Shigella spp.; Other Enterobacterales; Haemophilus influenzae / Complicated urinary tract infections (cUTI) | IND/CTA ready |
| Alphanosos | W16P0576 | 3e | Other | A. baumannii, P. aeruginosa, MRSA,N. gonorrhoeae, M. tuberculosis/Infectious skin conditions (eczema, acne, sporiasis, ...), difficult wounds | Pre-clinical |
| ALLECRA THERAPEUTICS | Cefepime / Enmetazobactam | 3d | NME | cUTI, AP | Phase III |
| Akthelia | AKT-011 | 3c | NME | Escherichia coli; Salmonella spp; Broad-spectrum G+/G-/GI infections | Lead opt |
| AiCuris Anti-infective Cures AG | Artilysins | 3a | Protein/Peptide | Undisclosed/Bloodstream infections, Diabetic foot infection | Lead opt |
| AGILeBiotics B.V. | ABX-395 | 3a | NME | Hospital-treated MDR Gram-negative infections | Lead opt |
| AGILeBiotics B.V. | ABX-605 (Maranmicin) | 3a | NME | A. baumannii; P. aeruginosa; Escherichia coli; Klebsiella pneumoniae; Enterobacter spp.; Citrobacter spp.; Staphylococcus aureus; Enterococcus faecium; Mycobacterium Avium Complex; Mycobacterium Abscessus/Cystic fibrosis associated infections - NTM | Pre-clinical |
| ABAC therapeutics | ABAC-39877 | 3a | NME | A. baumannii/Hospital infections | Pre-clinical |
| Da Volterra | DAV132 | 4b | Other | Prevention of C.difficile infections | Phase II |
